Dr. Rugo on Pathway Blockade in Breast Cancer

Dr. Rugo on the Efficacy of Bevacizumab in Breast CancerПодробнее

How prevalent are AKT Pathway alterations in breast cancer?Подробнее

Dr. Rugo on Extended Adjuvant Hormone Therapy for Breast CancerПодробнее

Dr. Rugo Discusses Guidelines for Metastatic Breast Cancer ManagementПодробнее

Dr. Rugo on Resistance to CDK4/6 Inhibitors in HR+ Breast CancerПодробнее

Dr. Rugo on PI3K and mTOR Inhibitors for the Treatment of Breast CancerПодробнее

Dr. Rugo Discusses the Future of Angiogenesis in Breast CancerПодробнее

Dr. Rugo on Pathway Changes in Breast CancerПодробнее

Dr. Rugo on Ongoing Trials in HER2+ Breast CancerПодробнее

Dr. Rugo on SWISH Trial for HR-Positive Breast CancerПодробнее

Dr Rugo on Managing Treatment-Limiting Toxicities in Breast CancerПодробнее

Dr. Hope Rugo Examines Angiogenesis Inhibition for Advanced Breast CancerПодробнее

CDK4/6 Inhibition in Breast CancerПодробнее

Dr. Rugo on Hormone Therapy for Patients With Breast CancerПодробнее

Dr. Rugo on the Advances in the Treatment of HER2-Positive Breast CancerПодробнее

Dr. Rugo on Chemotherapy for Metastatic Breast CancerПодробнее

Dr. Rugo on Guidelines for the Treatment of Metastatic Breast CancerПодробнее

Dr. Borgen Discusses HER2 Blockade in Breast CancerПодробнее

Dr. Rugo on the Future of Extended Adjuvant Hormone Therapy for Breast CancerПодробнее